Albertsons Hit With $900 Million Washington Opioid Judgment

• A Washington state judge ordered Albertsons to pay a $900 million judgment for its role in the opioid crisis.
• The court found Albertsons contributed to a public nuisance and violated the Washington Consumer Protection Act by neglecting to prevent opioid misuse and diversion.
• Evidence showed Albertsons failed to investigate suspicious orders, lacked proper safeguards, and did not conduct due diligence on red-flagged prescriptions.
• Albertsons repeatedly violated the Controlled Substances Act by prioritizing profits over patient safety, filling over 6.5 million red-flagged prescriptions without proper verification.
• The judge concluded Albertsons did not adequately staff pharmacies, train pharmacists, or establish an effective compliance department.

The court determined that the company neglected to investigate or report suspicious, high-volume opioid orders destined for its own pharmacies.

A Washington state judge has ordered Albertsons to pay a substantial $900 million judgment, finding the grocery pharmacy chain failed in its duty to prevent the misuse and diversion of addictive medications. King County Superior Court Judge Janet Helson issued the ruling on Thursday, concluding that Albertsons Companies, Inc. and Safeway, Inc. significantly contributed to the ongoing opioid public nuisance and violated the state's Consumer Protection Act through years of unfair practices.

The judgment follows a rigorous nine-week bench trial, where the state presented extensive evidence demonstrating Albertsons' systemic failures. The court determined that the company neglected to investigate or report suspicious, high-volume opioid orders destined for its own pharmacies. Furthermore, evidence showed that Albertsons maintained inadequate safeguards, which directly facilitated the diversion of prescription opioids into the black market, and consistently failed to conduct proper due diligence when dispensing staggering quantities of prescriptions that clearly indicated potential diversion.

Judge Helson's 219-page opinion underscored the devastating impact of the opioid crisis, describing it as a widespread and damaging epidemic affecting Washingtonians across urban, small-town, and rural areas. She emphasized that the crisis has severely interfered with public health, public safety, public spaces, and the daily lives of the state's residents, necessitating massive efforts to address and remedy its consequences.

As both a distributor and dispenser of prescription opioids, Albertsons is legally bound by the Drug Enforcement Administration (DEA) and the Controlled Substances Act to implement and maintain effective controls against diversion. However, the court found that Albertsons repeatedly violated the Controlled Substances Act by dispensing and distributing addictive painkillers in a manner that prioritized increasing its profits over patient safety and regulatory compliance.

The preponderance of evidence presented at trial clearly demonstrated that Albertsons never established or enforced policies and procedures robust enough to prevent the shipment of suspicious opioid orders to its stores, nor the dispensing of "red flag" prescriptions without the required due diligence. The state presented compelling evidence, including instances where tens of thousands of opioid pills were either diverted or inappropriately dispensed due to these failures. The court also found that Albertsons possessed, yet routinely disregarded or ignored, critical information and tools that could have prevented diversion, opting instead for sales and profits over the health and safety of Washingtonians.

This disregard for public well-being was deemed a substantial factor in the ongoing opioid crisis within the state. The court specifically noted that Albertsons, which operates over 200 pharmacies in Washington, filled more than 6.5 million red-flagged prescriptions without adequately documenting efforts to verify their legitimacy, further illustrating its systemic failure to meet its legal and ethical obligations under the Washington Consumer Protection Act opioid provisions and the broader Controlled Substances Act pharmacy liability requirements.

The court's findings highlighted significant deficiencies within Albertsons' operational structure and compliance efforts. Judge Helson determined that the company did not adequately staff its pharmacies, nor did it properly train its pharmacists on the critical protocols for dispensing controlled substances. Crucially, Albertsons also failed to establish an adequate compliance department, indicating a fundamental lack of commitment to preventing opioid diversion.

While acknowledging that numerous factors have contributed to the opioid epidemic—including misleading information from manufacturers, well-intentioned state policies, medical community guidance on pain management, and incompetent prescribers—Judge Helson firmly stated that the existence of these other factors, even substantial ones, does not excuse Albertsons' conduct. The judgment underscores the principle that each entity in the pharmaceutical supply chain bears responsibility for its role in preventing the crisis, and that prioritizing company profit over public health carries severe consequences.

This substantial judgment against Albertsons highlights the critical importance for pharmacies and distributors to implement and rigorously enforce effective controls against opioid diversion, conduct thorough due diligence on suspicious orders, and adequately staff and train compliance departments. Lawyers should advise clients in the pharmaceutical supply chain to review their current compliance protocols to mitigate significant financial and reputational risks under state consumer protection acts and the Controlled Substances Act.

Source: Original reporting via Courthouse News Service